Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Tumor Marker CYFRA 21-1 in NSCLC Patients (16 Months Folow up Study) (CROSBI ID 474782)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Pavićević, Radomir ; Bialk, Petra ; Miličić, Jasna ; Bubanović, Gordana ; Bobić, Jasminka ; Pavićević, Lukrecija Tumor Marker CYFRA 21-1 in NSCLC Patients (16 Months Folow up Study) // 1st Alps Adria Meeting on Human Genetics / Stavljenić Rukavina, Ana (ur.). Zagreb: Hrvatsko društvo za humanu genetiku, 2000. str. 111-111-x

Podaci o odgovornosti

Pavićević, Radomir ; Bialk, Petra ; Miličić, Jasna ; Bubanović, Gordana ; Bobić, Jasminka ; Pavićević, Lukrecija

engleski

Tumor Marker CYFRA 21-1 in NSCLC Patients (16 Months Folow up Study)

The serum level of CYFRA21-1 tumor marker has been longitudinally followed in 274 patients with NSCLC lung cancer after the surgery and chemotherapy, five times during 16 months (before the therapy, 1, 4, 10 and 16 months after the therapy. In 240 surgically treated patients the level of tumor marker CYFRA21-1 within 1 to 3 months fell down to the level oh healthy population, i.e. 0.3 to 2.5 ng/mL. The increase of serum level of CYFRA 21-1 was observed 3 months after surgery in 7 patients (6 M, 1 F), that underwent palliative resection. In 26 operated patients during longitudinal follow up noticed the increase of the serum level of CYFRA 21-1 tumor marker 1 to 3 months before other methods proved the relapse of the disease. In 20 patients the increase of the level of tumor marker CYFRA21-1was found at the same time when the relapse of the disease was objectivized with the usual clinical methods. In 6 patients with long distance metastases (Brain, Liver), without local relapse, the level of tumor marker CYFRA 21-1 did not increase. Out of 34 patients who were treated only with the chemotherapy in 20 the level of tumor marker CYFRA 21-1 fell down, in 9 the values increased and in 5 the results were the same as before the applied therapy. According to this results we can conclude that the follow up of tumor marker CYFRA21-1 in every patient after the therapy is very important, because the increase of its concentration show possible local relapse of the disease earlier than using other diagnostic methods. Follow up analysis of tumor marker CYFRA 21-1 in patients who were treated with the chemotherapy show that in 31% patient’s chemotherapy could not decrease the disease locally. We can also conclude that tumor marker CYFRA 21-1 is necessary in postoperative monitoring in patients with NSCLC, because the increase of its level is a good sign to detect relapse. This is the first part of three-year longitudinal study

tumor marker; CYFRA 21-1; NSCLC; anthropology; population genetics

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

111-111-x.

2000.

objavljeno

Podaci o matičnoj publikaciji

1st Alps Adria Meeting on Human Genetics

Stavljenić Rukavina, Ana

Zagreb: Hrvatsko društvo za humanu genetiku

Podaci o skupu

1st Alps Adria Meeting on human genetics

poster

14.04.2000-15.04.2000

Brijuni, Hrvatska

Povezanost rada

Etnologija i antropologija